×
Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    Asia Pacific Imaging Agents Market Forecast 2028 By Product Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, Barium-based Contrast Media), By Application (Oncology, Gastrointestinal, Cardiology, Neurology), By Modality (X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound), By End-use (Hospitals, Ambulatory Surgical Centers, Diagnostic & Imaging Centers), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Taiwan, Malaysia, Indonesia, Thailand), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: June 2022   |   Report ID: GR2143   |   Delivery: PDF  Request Free Sample

    Asia Pacific Imaging Agents Market size crossed USD 1.9 billion in 2021 and is projected to showcase around 5.3% growth rate between 2022 and 2028. The market growth is due to the rapid increase in the prevalence of stroke cases across the region that increases the demand for imaging procedures and contrast agents. Furthermore, major companies in the Asia Pacific region are focusing on the development of new generation CT angiograms and MRI for accurate diagnosis and treatment decisions.

    Asia Pacific Imaging Agents Market

    Get more details on this report - Request Free Sample PDF

    Asia Pacific Market, By Product Type

    Asia Pacific Imaging Agents Market

    Get more details on this report - Request Free Sample PDF

    Asia Pacific Market, By Application

    The neurology segment will grow at 5.2% CAGR during the forecast timeline, attributed to rising cases of Alzheimer’s disease across the region. For instance, according to the Alzheimer’s and Related Disorders Society of India (ARDSI), in 2020, approximately 5.3 million people above the age of 60 affected due to Dementia in India. Therefore, to detect similar diseases, molecular imaging is preferred, provides detailed images of the body at cellular and molecular level. Thus, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is used to measure physiological changes for detecting central nervous system disorders.

    Asia Pacific Market, By End-use

    The hospitals segment dominated over 42% Asia Pacific imaging agents market share 2021, due to rising adoption of advanced diagnostic systems by hospitals to detect and diagnose diseases coupled with increasing number of hospitals in Asia Pacific region. Moreover, emergency rooms provide quality care for patients who are experiencing more dangerous conditions, such as stroke, severe bleeding, trauma, and some types of infection is expected to drive the industry growth.

    Asia Pacific Market, By Modality

    The X-ray segments will witness CAGR of more than 5.1% from 2022 to 2028, owing to the rising demand for structural imaging and functional imaging procedure.  Structural imaging measures anatomical structure while functional imaging reveals changes in biological functions. For X-ray, iodinated molecules and barium-based contrast agents are widely used for diagnostic imaging methods. Also, X-ray imaging method widely supports medical and surgical treatment planning to treat tumours, blood clots, or blockage removal.

    Asia Pacific Market, By Country

    India imaging agents market was valued at USD 310 million in 2021, on account of rising cardiovascular diseases in the region. For instance, according to the Global Burden of Disease, in 2021, around 24.6% deaths were due to cardiovascular diseases in India. Moreover, increasing healthcare expenditure coupled with presence of presence of well-established local and international manufacturers in the area. For instance, General Electric Pharmaceuticals (Shanghai) Co., Ltd., is a GE Healthcare subsidiary that manufactures diagnostic pharmaceuticals (CT/MR contrast media) in China is one of the world's largest contrast media manufacturing facilities.

    Competitive Industry Landscape

    Prominent participants operating across the in the Asia Pacific imaging agents market include Bayer Healthcare Pharmaceuticals, Trivitron Healthcare, Guerbet Group, Bracco Diagnostics, Inc., GE Healthcare, Eli Lily, and Beijing Beilu Pharmaceutical Co Ltd.


    Frequently Asked Question(FAQ) :

    How big is the Asia Pacific imaging agents market?
    The market size for imaging agents in Asia Pacific was surpassed USD 1.9 billion in 2021 and is expected to depict a growth rate of 5.3% from 2022 to 2028 owing to a rapid rise in stroke cases.
    What will the growth rate of neurology imaging agents segment be, in the Asia Pacific region?
    The market size for neurology imaging agents in Asia Pacific is estimated to record a CAGR of 5.2% through 2028 considering an increase in Alzheimer cases in the region.
    How much is India imaging agents industry worth?
    The market value for imaging agents in India was exceeded USD 310 million in 2021 and will depict lucrative growth driven by the escalating number of cardiovascular diseases in the region.
    Which are major companies in the Asia Pacific imaging agents landscape?
    Prominent players in the APAC market comprise Guerbet Group, Bayer Healthcare Pharmaceuticals, GE Healthcare, Trivitron Healthcare, and others.

    Get this research report on Asia Pacific Imaging Agents Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

      (+1)-208-273-9852

     [email protected]